PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Ocuphire Pharma, Inc. (OCUP)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US67577R1023

CUSIP

67577R102

Sector

Healthcare

IPO Date

May 23, 2005

Highlights

Market Cap

$31.74M

EPS (TTM)

-$0.54

Total Revenue (TTM)

$2.82M

Gross Profit (TTM)

-$2.21M

EBITDA (TTM)

-$16.03M

Year Range

$1.07 - $2.65

Target Price

$13.67

Short %

3.74%

Short Ratio

10.10

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
OCUP vs. IVVD OCUP vs. SPY
Popular comparisons:
OCUP vs. IVVD OCUP vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Ocuphire Pharma, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%-5.00%0.00%5.00%10.00%Aug 25SeptemberSep 08Sep 15Sep 22Sep 29Oct 06Oct 13Oct 20
-11.11%
3.36%
OCUP (Ocuphire Pharma, Inc.)
Benchmark (^GSPC)

Returns By Period


OCUP

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

4.46%

1M

2.46%

6M

9.31%

1Y

23.49%

5Y*

13.03%

10Y*

11.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of OCUP, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-12.96%-3.24%-20.71%-21.14%5.99%-8.93%30.07%-37.69%5.65%-62.46%
2023-1.70%-0.58%8.70%36.80%-24.76%12.44%-0.23%-7.85%-16.04%-14.93%7.02%-1.31%-14.73%
2022-15.01%7.89%-5.26%-27.78%-9.40%-9.43%-2.60%21.39%-11.45%16.92%31.06%14.61%-5.36%
202179.82%-9.08%-45.24%-12.39%-10.81%16.30%-20.45%5.95%15.73%-23.50%-0.76%-4.60%-42.53%
20207.33%13.66%-22.75%5.61%32.03%13.15%-6.34%-14.29%-8.77%3.37%-28.37%5.36%-15.05%
2019-30.86%-19.36%-1.64%-2.78%-17.14%4.67%-0.78%-57.23%-6.39%-18.05%2.98%10.40%-82.89%
20183.47%-23.44%-5.63%15.23%28.74%-37.05%7.09%13.91%3.49%-35.39%-6.09%-13.89%-53.96%
201721.42%44.52%104.82%-15.63%-11.69%-24.74%-26.22%14.22%0.41%-27.27%22.16%-6.05%42.35%
2016-0.88%-3.28%-5.14%-9.12%6.67%-21.50%4.50%-4.38%-16.33%-20.62%-0.96%-14.05%-60.91%
20154.29%9.52%-8.69%-1.37%1.97%-17.23%-11.19%6.17%-9.25%-14.71%1.69%-19.51%-48.14%
2014125.49%17.39%-20.00%-12.08%-3.00%-5.54%-13.78%-6.68%15.71%-11.22%-6.48%4.09%37.25%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of OCUP is 7, meaning it’s performing worse than 93% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of OCUP is 77
Overall Rank
The Sharpe Ratio Rank of OCUP is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of OCUP is 55
Sortino Ratio Rank
The Omega Ratio Rank of OCUP is 77
Omega Ratio Rank
The Calmar Ratio Rank of OCUP is 1111
Calmar Ratio Rank
The Martin Ratio Rank of OCUP is 66
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Ocuphire Pharma, Inc. (OCUP) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
OCUP
^GSPC

There is not enough data available to calculate the Sharpe ratio for Ocuphire Pharma, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00Aug 25SeptemberSep 08Sep 15Sep 22Sep 29Oct 06Oct 13Oct 20
-0.91
2.98
OCUP (Ocuphire Pharma, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Ocuphire Pharma, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%Aug 25SeptemberSep 08Sep 15Sep 22Sep 29Oct 06Oct 13Oct 20
-99.96%
-0.93%
OCUP (Ocuphire Pharma, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Ocuphire Pharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ocuphire Pharma, Inc. was 99.96%, occurring on Oct 24, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.96%May 28, 20084132Oct 24, 2024
-78%Sep 25, 200635Dec 26, 2006209May 27, 2008244
-75%Aug 26, 200558Jun 27, 200611Aug 29, 200669
-23.08%Jul 14, 20051Jul 14, 20051Jul 27, 20052
-16.67%May 26, 20051May 26, 20051Jun 1, 20052

Volatility

Volatility Chart

The current Ocuphire Pharma, Inc. volatility is 17.42%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%30.00%Aug 25SeptemberSep 08Sep 15Sep 22Sep 29Oct 06Oct 13Oct 20
17.42%
2.75%
OCUP (Ocuphire Pharma, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Ocuphire Pharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Ocuphire Pharma, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab